Scholarlink

<p>This study introduces a novel Acyclovir-loaded cubosomal nanoparticle system incorporated into an in-situ gelling formulation, designed to address the limitations of conventional eye drops in treating herpes keratitis—a leading cause of corneal blindness. Herpes keratitis symptoms, including redness, itching, tearing, and irritation, are driven by inflammatory mediators released from mast cells, eosinophils, and corneal nerves. To combat these, Olopatadine Hydrochloride, a dual-acting H1 antihistamine and mast cell stabilizer, was integrated into the formulation for rapid symptomatic relief. Monoolein was selected as the lipid matrix for cubosome formation, stabilized with Poloxamer 407 using a top-down technique, and embedded in a thermosensitive Gellan gum gel for improved pre-ocular retention and controlled release. The optimized system demonstrated 93.58% Acyclovir and 95.24% Olopatadine release with zero-order kinetics, excellent bioadhesion, isotonicity, and sterility after 14 days of UV sterilization. Stability studies revealed no significant changes in physicochemical parameters, highlighting robustness. The cubosomal in-situ gel significantly enhanced ocular bioavailability and permeability, reduced dosing frequency, minimized systemic side effects, and provided controlled drug release. This innovative approach offers a promising therapeutic solution for herpes keratitis, combining targeted antiviral action with effective anti-inflammatory relief, and represents a major advancement in ocular nanomedicine for improved patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of Liquid Crystalline Nanoparticles for Effective Treatment of Herpes Keratitis

  • 期刊论文

  • 发表日期：

    2026年1月27日

查看全文
  • Himanshu Sharma,
  • Nipun Panchal,
  • Prabha Singh

摘要

This study introduces a novel Acyclovir-loaded cubosomal nanoparticle system incorporated into an in-situ gelling formulation, designed to address the limitations of conventional eye drops in treating herpes keratitis—a leading cause of corneal blindness. Herpes keratitis symptoms, including redness, itching, tearing, and irritation, are driven by inflammatory mediators released from mast cells, eosinophils, and corneal nerves. To combat these, Olopatadine Hydrochloride, a dual-acting H1 antihistamine and mast cell stabilizer, was integrated into the formulation for rapid symptomatic relief. Monoolein was selected as the lipid matrix for cubosome formation, stabilized with Poloxamer 407 using a top-down technique, and embedded in a thermosensitive Gellan gum gel for improved pre-ocular retention and controlled release. The optimized system demonstrated 93.58% Acyclovir and 95.24% Olopatadine release with zero-order kinetics, excellent bioadhesion, isotonicity, and sterility after 14 days of UV sterilization. Stability studies revealed no significant changes in physicochemical parameters, highlighting robustness. The cubosomal in-situ gel significantly enhanced ocular bioavailability and permeability, reduced dosing frequency, minimized systemic side effects, and provided controlled drug release. This innovative approach offers a promising therapeutic solution for herpes keratitis, combining targeted antiviral action with effective anti-inflammatory relief, and represents a major advancement in ocular nanomedicine for improved patient outcomes.